PolarSeal has announced the opening of an Innovation Lab at its new headquarters in Farnborough Business Park, Hampshire.
The new facility will enable MedTech teams to move from concept to scaled products faster.
With demand for rapid, reliable product development growing rapidly across the medical device sector, the facility provides customers with an environment that reduces early-stage uncertainty, speeds up feasibility decisions and shortens the path towards manufacturable solutions.
In an industry where timelines are tightening and innovation cycles are accelerating, the Innovation Lab represents a strategic investment, giving MedTech partners earlier access to PolarSeal’s material science expertise, advanced adhesives knowledge and applied engineering insight.
By enabling the structured exploration at the very start of the development pathway, the space supports customers in making confident decisions before committing to full-scale engineering.
Designed as a flexible hands-on environment, the lab features dedicated spaces for feasibility work, materials exploration and structured co-creation sessions.
Writable surfaces, digital collaboration tools, sector-specific demonstration areas and access to specialist materials allow teams to rapidly test assumptions, evaluate options and understand real-world constraints earlier than ever before.
Chris Locke, Chief Technology Officer at PolarSeal, said: "The Innovation Lab is built around what early-stage development really needs: speed, clarity and confidence."
"MedTech teams want to validate feasibility quickly, reduce risk and progress ideas without delay."
"This new space enables fast, practical exploration of materials and adhesives, enabling product developers to move forward with certainty in a market that demands rapid innovation.”
Complementing the new Innovation Lab, PolarSeal will also unveil its new Prototype Lab early in 2026, offering the capability to convert early concepts into test-ready prototypes.
Together, these two facilities create a seamless, end-to-end pathway — from initial exploration to production-ready components.
This will enable customers to reduce development cycles and bring new medical devices to market more efficiently.
Oliver Law, Fractional CEO, said: "This investment reinforces our long-term commitment to supporting MedTech partners at every stage of development."
"The Innovation Lab is where ideas take shape and the Prototype Lab ensures they evolve into viable, reliable outcomes."
"Together, they enhance the speed, quality and certainty we can offer customers, bringing new medical devices to market."